澤璟製藥(688266.SH)發行價確定為33.76元/股 1月14日申購
格隆匯1月12日丨澤璟製藥(688266.SH)發佈首次公開發行股票並在科創板上市發行公告,協商確定此次發行價格為33.76元/股,網下發行不再進行累計投標詢價。
投資者請按此價格在2020年1月14日(T日)進行網上和網下申購,申購時無需繳付申購資金。其中,網下申購時間為9:30-15:00,網上申購時間為9:30-11:30,13:00-15:00。
此次發行初始戰略配售數量為300萬股,佔發行總數量的5.00%,戰略投資者承諾的認購資金已於規定時間內全部匯至聯席主承銷商指定的銀行賬户。此次發行最終戰略配售數量為180萬股,佔發行總數量的3%。初始戰略配售與最終戰略配售股數的差額120萬股將回撥至網下發行。
依據發行人與聯席主承銷商協商確定的發行價格33.76元/股,此次發行規模為人民幣20.26億元。根據《業務指引》規定,此次發行規模超過人民幣20億元、不足50億元,根據《業務指引》規定,此次發行保薦機構相關子公司跟投比例為發行數量的3%,但不超過人民幣1億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.